REYON Pharmaceutical Co., Ltd.
REYON Pharmaceutical Co., Ltd. (KRX: 102460) is trading at ₩10,280.00, about ₹742 at today's KRW/INR rate, as of 8 Oct 2026, 2:30 AM ET, up 0.39% today. REYON Pharmaceutical is not currently available to trade on Paasa; this page shows its price, statistics and the Indian tax treatment for information.
Quote
Today's low
₩10,010.00
Today's high
₩10,360.00
52 week low
₩9,100.00
52 week high
₩13,200.00
102460 opened at ₩10,240.00, closed previously at ₩10,240.00, and has traded between ₩9,100.00 and ₩13,200.00 over the past 52 weeks.
About
Operating both domestically in South Korea and across international markets, REYON Pharmaceutical Co., Ltd. specializes in the production and distribution of pharmaceutical products and active pharmaceutical ingredients (APIs). The company's diverse range of offerings addresses various therapeutic areas, including adrenal corticosteroids; angiotensin II receptor antagonists; anticholinergics; antiemetics; antihypertensives; anti-inflammatory enzymes; lipid-lowering, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer treatments; antispasmodics; benign prostatic hypertrophy therapies; cough and cold remedies; cardiac stimulants; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis medications; local anesthetics; migraine drugs; a variety of cardiovascular system drugs; medications for neuromuscular disorders; nootropics and neurotonics; non-steroidal anti-inflammatory drugs (NSAIDs); respiratory stimulants; skeletal muscle relaxants; and vasodilators. Established in 1955, REYON Pharmaceutical Co., Ltd. maintains its corporate headquarters in Seoul, South Korea.
Key statistics
Avg. volume
48.60K
Market cap
₩188.55B
P/E Ratio
-5.50
Price-to-sales ratio
1.32
Enterprise value
₩409.82B
Free cash flow yield
-3.34%
Debt-to-equity ratio
1.11
Return on equity
-13.55%
ROIC
-7.20%
Beta
0.39
Dividend yield
0.00%
Last dividend
₩0.00
Financial overview
Revenue
₩145.93B
Earnings per share
-₩1,604.66
Free cash flow
-₩6.69B
Net profit margin
-24.02%
Gross margin
21.48%
EBITDA
₩228.10M
Revenue growth
-1.60%
Similar securities
This is not an investment recommendation
REYON Pharmaceutical for Indian investors
REYON Pharmaceutical is listed on the Korea Exchange. It is not currently available to trade on Paasa; the figures on this page are for information, and the tax notes below apply to Indian residents who hold it.
Taxes on REYON Pharmaceutical for Indian residents
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm KST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneREYON Pharmaceutical does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
FAQs
Can I buy REYON Pharmaceutical on Paasa?
REYON Pharmaceutical (102460) has been listed on the Korea Exchange since 2010, in the Drug Manufacturers - Specialty & Generic industry. REYON Pharmaceutical is not currently available to trade on Paasa; the figures on this page are for information. Indian residents who hold it through another broker still declare it under the rules below.
How much does one REYON Pharmaceutical share cost in rupees?
One REYON Pharmaceutical share is ₩10,280.00 — about ₹742 at a KRW/INR rate of 0.0722 on 8 Oct 2026. Both the REYON Pharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for investing abroad from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability.
How are gains on REYON Pharmaceutical shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the KRW/INR rate on the purchase and the sale date, so the rupee move counts alongside the REYON Pharmaceutical price.
Does REYON Pharmaceutical pay a dividend?
No. REYON Pharmaceutical does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one: dividends are taxed at your slab rate in India.
When does KRX trade, in Indian time?
The Korea Exchange trades 5:30 am – 12:00 pm IST in Indian time.
Do I have to declare REYON Pharmaceutical shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. The holding is reported with its cost and its closing value.
Does the rupee rate affect what I make on REYON Pharmaceutical?
Yes. REYON Pharmaceutical is priced in KRW, so your rupee outcome combines the KRW move with the KRW/INR move between the day you remit and the day you convert back.